

### AMENDMENTS TO THE CLAIMS

The listing of claims provided below will replace all prior versions, and listings, of claims in the application.

#### Listing of claims

1. (Currently amended) A method of improving gene therapy by increasing the level of expression of a recombinant protein corresponding to an individual's endogenous protein *in vivo* in cells of an individual, wherein the recombinant protein is expressed from an expression vector which has been introduced into the cells, which method comprises administering to the individual an active site-specific chaperone of the protein, with the proviso that the individual's endogenous protein is not a mutant, ~~endogenous~~ protein that is deficient due to defective folding or processing in the endoplasmic reticulum.

2. (Original) The method of claim 1, wherein the vector is a viral vector.


3. (Original) The method of claim 2, wherein the viral vector is an adenoviral vector.

4. (Original) The method of claim 1, wherein the protein is an enzyme and the active site-specific chaperone is a reversible competitive inhibitor of the enzyme.

5. (Original) The method of claim 4, wherein the enzyme is  $\alpha$ -galactosidase A.

6. (Withdrawn) The method of claim 4, wherein the enzyme is  $\beta$ -glucocerebrosidase.

7. (Original) The method of claim 5, wherein the reversible competitive inhibitor is a compound of the following formula:



wherein R<sub>0</sub> represents H or a C<sub>1</sub>-C<sub>12</sub> alkyl chain;

R<sub>1</sub> and R<sub>1</sub>' independently represent H, OH, a 1-4 carbon alkyl, alkoxy or hydroxyalkyl group;

R<sub>2</sub> and R<sub>2</sub>' independently represent H, OH or a C<sub>1</sub>-C<sub>12</sub> alkyl group


R<sub>4</sub> and R<sub>4</sub>' independently represent H, OH; and

R<sub>7</sub> represents H or OH.

8. (Original) The method of claim 7, wherein the reversible competitive inhibitor is a compound selected from the group consisting of 1-deoxygalactonojirimycin,  $\alpha$ -*allo*-homonojirimycin,  $\alpha$ -*galacto*-homonojirimycin,  $\alpha$ -1-C-butyl-deoxynojoirimycin, calystegine A<sub>3</sub>, calystegine B<sub>2</sub>, N- methyl-calystegine A<sub>3</sub>, and N-methyl-calystegine B<sub>2</sub>.

9. (Original) The method of claim 7, wherein the reversible competitive inhibitor is 1-deoxygalactonojirimycin.

10. (Withdrawn) The method of claim 6, wherein the reversible competitive inhibitor is a compound of the following formula:



wherein R<sub>0</sub> represents H or a C<sub>1</sub>-C<sub>12</sub> alkyl chain;

R<sub>0</sub>' represents H, a straight chain or branched saturated carbon chain containing 1-12 carbon atoms, optionally substituted with a phenyl, hydroxyl or cyclohexyl group;  
R<sub>1</sub> and R<sub>1</sub>' independently represent H, OH, a 1-4 carbon alkyl, alkoxy or hydroxyalkyl group; and  
R<sub>2</sub> and R<sub>2</sub>' independently represent H, OH or a C<sub>1</sub>-C<sub>12</sub> alkyl group.

11. (Withdrawn) The method of claim 10, wherein the reversible competitive inhibitor is a compound selected from the group consisting of isofagomine, N-dodecyl-isofagomine, N-nonyl-isofagomine, N-dodecyl-deoxynojirimycin, calystegine A<sub>3</sub>, calystegine B<sub>2</sub>, calystegine B<sub>3</sub> and calystegine C<sub>1</sub>.

12. (Withdrawn) The method of claim 11, wherein the reversible competitive inhibitor is isofagomine.

13. (Withdrawn) The method of claim 11, wherein the reversible competitive inhibitor is N-dodecyl-isofagomine.

14. (Currently amended) A method of improving gene therapy in an individual by increasing the level of expression of a recombinant protein corresponding to an individual's endogenous protein *in vivo*, wherein the recombinant protein is expressed by host cells comprising an expression vector encoding the recombinant protein, which method comprises co-administering to the individual the host cells and an effective amount of an active-site specific chaperone of the protein, with the proviso that the individual's endogenous protein is not a mutant, ~~endogenous~~ protein that is deficient due to defective folding or processing in the endoplasmic reticulum.

15. (Original) The method of claim 14, wherein the vector is a viral vector.

16. (Original) The method of claim 15, wherein the viral vector is an adenoviral vector.

17. (Original) The method of claim 15, wherein the host cells are human primary cells and the individual is a human.


18. (Original) The method of claim 17, wherein the human cells are mesenchymal stem cells.

19. (Original) The method of claim 14, wherein the protein is an enzyme.

20. (Original) The method of claim 19 wherein the enzyme is  $\alpha$ -galactosidase A.

21. (Withdrawn) The method of claim 19, wherein the enzyme is  $\beta$ -glucocerebrosidase.

22. (Original) The method of claim 20, wherein the reversible competitive inhibitor is a compound of the following formula:



wherein  $R_0$  represents H or a  $C_1$ - $C_{12}$  alkyl chain;

$R_1$  and  $R_1'$  independently represent H, OH, a 1-4 carbon alkyl, alkoxy or hydroxyalkyl group;

$R_2$  and  $R_2'$  independently represent H, OH or a  $C_1$ - $C_{12}$  alkyl group


$R_4$  and  $R_4'$  independently represent H, OH; and

$R_7$  represents H or OH.

23. (Original) The method of claim 22, wherein the reversible competitive inhibitor is a compound selected from the group consisting of 1-deoxygalactonojirimycin,  $\alpha$ -allo-homonojirimycin,  $\alpha$ -galacto-homonojirimycin,  $\alpha$ -1-C-butyl-deoxynojirimycin, calystegine A<sub>3</sub>, calystegine B<sub>2</sub>, N-methyl-calystegine A<sub>3</sub>, and N-methyl-calystegine B<sub>2</sub>.

24. (Original) The method of claim 23, wherein the reversible competitive inhibitor is 1-deoxygalactonojirimycin.

25. (Withdrawn) The method of claim 21, wherein the reversible competitive inhibitor is a compound of the following formula:



wherein  $R_0$  represents H or a  $C_1$ - $C_{12}$  alkyl chain;

$R_0'$  represents H, a straight chain or branched saturated carbon chain containing 1-12 carbon atoms, optionally substituted with a phenyl, hydroxyl or cyclohexyl group;

$R_1$  and  $R_1'$  independently represent H, OH, a 1-4 carbon alkyl, alkoxy or hydroxyalkyl group; and

$R_2$  and  $R_2'$  independently represent H, OH or a  $C_1$ - $C_{12}$  alkyl group.

26. (Withdrawn) The method of claim 25, wherein the reversible competitive inhibitor is a compound selected from the group consisting of isofagomine, N-dodecyl-isofagomine, N-nonyl-isofagomine, N-dodecyl-deoxynojirimycin, calystegine A<sub>3</sub>, calystegine B<sub>2</sub>, calystegine B<sub>3</sub> and calystegine C<sub>1</sub>.

27. (Withdrawn) The method of claim 26, wherein the reversible competitive inhibitor is isofagomine.

28. (Withdrawn) The method of claim 26, wherein the reversible competitive inhibitor is N-dodecyl-isofagomine.

29. (Currently amended) A method of improving treatment in an individual being administered a therapeutic vector comprising a gene encoding a protein corresponding to an

individual's endogenous protein, comprising co-administering to the individual an active site-specific chaperone for the protein, with the proviso that the individual's endogenous protein is not a mutant, endogenous protein that is deficient due to defective folding or processing in the endoplasmic reticulum.


30. (Original) The method of claim 29, wherein the protein is an enzyme and the active site-specific chaperone is an inhibitor of the enzyme.

31. (Original) The method of claim 30 wherein the enzyme is associated with a lysosomal storage disorder.

32. (Original) The method of claim 31, wherein the enzyme is  $\alpha$ -galactosidase A.

33. (Withdrawn) The method of claim 31, wherein the enzyme is  $\beta$ -glucocerebrosidase.

34. (Original) The method of claim 32, wherein the reversible competitive inhibitor is a compound of the following formula:



wherein  $R_0$  represents H or a  $C_1$ - $C_{12}$  alkyl chain;

$R_1$  and  $R_1'$  independently represent H, OH, a 1-4 carbon alkyl, alkoxy or hydroxyalkyl group;

$R_2$  and  $R_2'$  independently represent H, OH or a  $C_1$ - $C_{12}$  alkyl group


$R_4$  and  $R_4'$  independently represent H, OH; and

$R_7$  represents H or OH.

35. (Original) The method of claim 34, wherein the reversible competitive inhibitor is a compound selected from the group consisting of 1-deoxygalactonojirimycin,  $\alpha$ -*allo*-homonojirimycin,  $\alpha$ -*galacto*-homonojirimycin,  $\alpha$ -1-C-butyl-deoxynojirimycin, calystegine A<sub>3</sub>, calystegine B<sub>2</sub>, N-methyl-calystegine A<sub>3</sub>, and N-methyl-calystegine B<sub>2</sub>.

36. (Original) The method of claim 35, wherein the reversible competitive inhibitor is 1-deoxygalactonojirimycin.

37. (Withdrawn) The method of claim 33, wherein the reversible competitive inhibitor is a compound of the following formula:



wherein R<sub>0</sub> represents H or a C<sub>1</sub>-C<sub>12</sub> alkyl chain;

R<sub>0</sub>' represents H, a straight chain or branched saturated carbon chain containing 1-12 carbon atoms, optionally substituted with a phenyl, hydroxyl or cyclohexyl group;

R<sub>1</sub> and R<sub>1</sub>' independently represent H, OH, a 1-4 carbon alkyl, alkoxy or hydroxyalkyl group; and

R<sub>2</sub> and R<sub>2</sub>' independently represent H, OH or a C<sub>1</sub>-C<sub>12</sub> alkyl group.

38. (Withdrawn) The method of claim 37, wherein the reversible competitive inhibitor is a compound selected from the group consisting of isofagomine, N-dodecyl-isofagomine, N-nonyl-isofagomine, N-dodecyl-deoxynojirimycin, calystegine A<sub>3</sub>, calystegine B<sub>2</sub>, calystegine B<sub>3</sub> and calystegine C<sub>1</sub>.

39. (Withdrawn) The method of claim 38, wherein the reversible competitive inhibitor is isofagomine.

40. (Withdrawn) The method of claim 38, wherein the reversible competitive inhibitor is N-dodecyl-isofagomine.